Athens, 10th February: The IDEAL Project has officially launched in Athens with its first Consortium Meeting, led by the University of the Aegean. This pioneering EU-funded initiative is set to transform democratic participation by addressing one of Europe’s greatest challenges - language barriers in political engagement.
A recent study explained the mechanisms by which pulsed electromagnetic field therapy enhances doxorubicin uptake, paving the way for precision-driven cancer therapies with fewer side effects
N4 Pharma Plc the specialist preclinical stage biotech company announces a new lead programme, N4 101. This orally-delivered inflammation inhibitor for Irritable Bowel Disease (IBD) uses Nuvec®, the company’s novel silica non-viral, non-lipid nanoparticle delivery system, to overcome the challenges with current IBD treatments.
Linkam's updated CMS196V4 stage features an improved user interface with a touch-panel and joystick, an encoded and motorised XY stage and a newly interchangeable optical bridge for imaging, amongst other updated features. It enables researchers to investigate samples at cryogenic temperatures down to < -195 °C with ease.
TORSKAL is an international biotechnology company, a pioneer of green nanotechnology. We design disruptive gold nanoparticles for cancer therapy using green chemistry.
Infinite 8 Industries announces the discovery of Particle 11, a groundbreaking dark matter candidate with revolutionary energy potential, capable of transforming energy storage, quantum computing, and dark matter research.
Satisfied Users & 
Approved Press Releases
